1. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas;Ahmed A.;J. Immunol.,1970
2. Vaccines consisting of periodate-cleaved oligosaccharide from the capsule of H. influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant;Anderson P. W.;J. Immunol.,1986
3. Benenson A. S. 1976. Review of experience with whole-cell and somatic antigen vaccines p. 228-242. In H. Fukumi and Y. Zinnaka (ed.) Proceedings of the 12th Joint Conference of US Japan Cooperative Medical Sciences Program Cholera Panel.
4. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without B subunit of cholera toxin;Black R. E.;Infect. Immun.,1987
5. Occurrence of 2-keto-deoxyoctonic acid 5-phosphate in lipopolysaccharides of Vibrio cholerae Ogawa and Inaba;Brade H.;J. Bacteriol.,1985